Handelsavisen
prelaunch
Companies ›Healthcare ›ACHU.BO
AC
ACHU.BO — BSE (India) Pharmaceuticals

Achu.Bo

$4,93
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-7,1 %
ROE
1,8 %
Net margin
18,0 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

ACHU.BO operates in the pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products.

Business. ACHU.BO operates in the pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
1,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ACHU.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ACHU.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ACHU.BO operates in the pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 9.32, indicating a significant ability to meet short-term obligations. The absence of long-term debt and a debt-to-equity ratio of 0 suggests a conservative capital structure. However, the company reported negative operating cash flow of -40.64 million INR and free cash flow of -103.01 million INR, indicating cash outflows from operations.

    Profitability metrics show a return on equity of 1.75% and a return on assets of 1.68%, which are below the typical thresholds for pharmaceutical companies. The company reported a net income of 54.77 million INR despite an operating loss of 21.76 million INR, suggesting non-operating income or gains contributed to profitability.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This concentration may expose the company to higher risk if market conditions in its primary market deteriorate.

    The company's growth trajectory is uncertain, as the financial data does not provide forward-looking revenue projections. The negative operating cash flow and free cash flow indicate potential challenges in sustaining operations without external financing.

    The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the high current ratio support the low liquidity risk rating. However, the negative operating cash flow may require monitoring for future liquidity pressures.

    Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company has not disclosed any major strategic initiatives or new product launches in the latest filings.

    Key takeaways
    • ACHU.BO has a strong liquidity position with a current ratio of 9.32 and no long-term debt.
    • The company's profitability is modest, with a return on equity of 1.75% and a return on assets of 1.68%.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company reported negative operating and free cash flows, indicating potential operational challenges.
    • Risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
    • "margin_outlook_rationale": "The company's margin outlook is uncertain due to the reported operating loss and negative operating cash flow.",

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $4,93
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $313.0M
    Net cashⓘ
    $10.0M
    Current ratioⓘ
    9.3
    Debt / equityⓘ
    0.0
    ROAⓘ
    1.7%
    ROEⓘ
    1.8%
    Cash conversionⓘ
    -742.0%
    CapEx / revenueⓘ
    -3.6%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-7,1 %Below median
    Net Margin18,0 %Above P75
    ROE1,8 %Below median
    Capex / Rev-356,5 %Bottom quartile
    D/E0,00Above P75
    Cash Conv-7,42Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ACHU.BO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ACHU.BOCanonical
    BSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage